Adynxx (ADYX) 10-Q 14 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 07, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		5,005,211

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 1,536	$ 2,181
Accounts receivable, net	4,029	3,243
Inventory, net	1,655	1,551
Prepaid expenses and other current assets	161	185
Current assets of discontinued operations	217	317
Total current assets	7,598	7,477
Improvements and equipment, net	1,385	1,563
Intangible assets, net	20,935	22,069
Goodwill, net	1,659	1,659
Other assets	173	173
Total assets	31,750	32,941
Current Liabilities:
Accounts payable	2,875	1,641
Accrued expenses and other current liabilities	5,125	4,270
Senior secured term loan, net	12,831	10,929
Warrant liability	149	130
Total current liabilities	20,980	16,970
Other long-term liabilities	295	304
Total liabilities	21,275	17,274
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 5,005,211 and 4,986,034 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	5	5
Additional paid-in capital	165,590	165,672
Accumulated deficit	(155,120)	(150,010)
Total stockholders’ equity	10,475	15,667
Total liabilities and stockholders’ equity	$ 31,750	$ 32,941

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	5,005,211	4,986,034
Common stock, shares outstanding	5,005,211	4,986,034

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, net of returns, allowances and discounts	$ 5,381	$ 4,125
Cost of revenues	1,704	1,515
Gross profit	3,677	2,610
Operating expenses
Selling, general and administrative	7,029	7,588
Royalties	266	186
Research and product development	0	111
Transactional costs	923	634
Change in fair value of contingent consideration liability	0	35
Total operating expenses	8,218	8,554
Loss from operations	(4,541)	(5,944)
Other (expense) income
Interest expense	(548)	(573)
Interest income	1	2
Change in fair value of warrant liability	(19)	118
Warrant modification expense	0	(770)
Total other expense	(566)	(1,223)
Loss from continuing operations before tax	(5,107)	(7,167)
Income tax expense	(3)	(3)
Loss from continuing operations	(5,110)	(7,170)
Discontinued operations:
Income from discontinued operations, net of tax of $0 for the three months ended March 31, 2018 and 2017	0	172
Net loss	$ (5,110)	$ (6,998)
Net loss per basic and diluted common share:
Loss from continuing operations	$ (1.19)	$ (2.33)
Income from discontinued operations	0	0.06
Net loss per basic and diluted common share	$ (1.19)	$ (2.27)
Weighted average shares used in computing net loss per basic and diluted common share	4,302,608	3,071,342

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Activities
Net loss	$ (5,110)	$ (6,998)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,312	1,382
Amortization of deferred lease incentive	(11)	(11)
Deferred income tax expense	3	3
Provision for doubtful accounts	155	7
Reserve for note receivable	0	350
Provision for excess and slow moving inventory	0	23
Stock-based compensation expense	(80)	491
Deferred rent	(1)	2
Amortization of debt issuance and discount costs	190	204
Warrant modification expense	0	770
Change in fair value of warrant liability	19	(118)
Fair value adjustment of contingent consideration liability	0	35
Changes in operating assets and liabilities:
Accounts receivable	(941)	(108)
Inventory	(104)	48
Prepaid expenses and other assets	24	227
Accounts payable	1,234	(301)
Accrued expenses and other liabilities	855	(652)
Net Cash Used in Operating Activities	(2,455)	(4,646)
Investing Activities
Purchase of improvements and equipment	0	(39)
Issuance of bridge loan	0	(350)
Proceeds from escrow	100	0
Net Cash Provided by (Used In) Investing Activities	100	(389)
Financing Activities
Contingent purchase price payments	0	(675)
Net proceeds from bridge loan	1,712	0
Net proceeds from issuance of common stock	0	2,534
Payment of withholding taxes related to stock-based employee compensation	(2)	(54)
Net Cash Provided by Financing Activities	1,710	1,805
Net Decrease in Cash and Cash Equivalents	(645)	(3,230)
Cash and Cash Equivalents - Beginning of year	2,181	5,580
Cash and Cash Equivalents - End of year	1,536	2,350
Supplemental Disclosure of Cash Flows Information
Cash paid during the period for: Interest	362	370
Non-cash investing and financing activities:
Common stock issued for contingent purchase price payments	$ 0	$ 675

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. Recent Developments On January 5, 2018, the Company entered into an Asset Purchase Agreement (the “APA”) with Celularity, Inc. (“Celularity”) pursuant to which the Company agreed to sell substantially all of its assets to Celularity (the “Asset Sale Transaction”), including certain assets comprising its MIST, Biovance and Interfyl Product lines (the “Purchased Assets”). As consideration for the Purchased Assets, Celularity paid consideration to the Company $ 29 Under the terms of the APA, the Company will retain certain specified assets, including, among other things, cash, accounts receivable, and its hydrogel contract manufacturing business, including its SilverSeal and Hydress product lines. The transactions contemplated by the APA were approved by the affirmative vote of a majority of the voting power of issued and outstanding shares of the Company’s common stock on April 27, 2018. The AST was completed on May 7, 2018. The Company’s operations sold under the APA have not been reclassified to discontinued operations since they are classified as Held for Use. These operations are presented in continuing operations in the first quarter of 2018. These operations will be reclassified to discontinued operations in the second quarter of 2018, when the shareholders of the company approved the sale. (See Note 12 – Subsequent Events) The Company has, historically, served as a contract manufacturer, supplying the manufactured gels to third parties who incorporate them into their own products and will continue to manufacture said hydrogels going forward. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of March 31, 2018 and results of operations and cash flows for the three months ended March 31, 2018 and 2017. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. In order to add capital and to focus on future investments on commercializing its own regenerative technologies on August 31, 2017 the Company entered into an Asset Purchase Agreement (“the Argentum Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Argentum Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $ 3.6 112,000 3.6 300,000 100,000 200,000 Three Months Ended March 31, 2017 Revenue, net of returns, allowances and discounts $ 469 Cost of revenues 145 Gross profit 324 Selling, general and administrative 152 Income from discontinued operations, net of tax 172 Non-cash amortization expense of $ 74,000 March 31, December 31, 2018 2017 Accounts receivable, net $ 17 $ 17 Escrow 200 300 Total assets 217 317 Recent Accounting Principles In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	2. Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of March 31, 2018, the Company had a cash balance of approximately $ 1.5 5.1 2.5 155.1 12.8 29

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	3. Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing accounting principles generally accepted in the United States of America (“U.S. GAAP”) including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. The Company recognizes revenue primarily from two different types of contracts, (i) product sales to customers and (ii) contract manufacturing. Revenue from sales of products as well as from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. To achieve this core principle, the Company applies the following five steps: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – When an asset is transferred, and the customer obtains control of the asset (or the services are rendered), the Company recognizes revenue. At contract inception, the Company determines if each performance obligation is satisfied at a point in time or over time. Revenue from sales of products as well as from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. Disaggregation of Revenue The following table presents our disaggregated revenues by revenue source (in millions). The Company recognizes revenue primarily from two different types of contracts, (i) product sales to customers and (ii) contract manufacturing. Revenue from sales of products as well as from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. Three Months Ended March 31, 2018 2017 Product $ 4,841 $ 3,896 Contract manufacturing 540 229 Total revenues, net $ 5,381 $ 4,125 As of March 31, 2018, or December 31, 2017, the Company did not have any contract assets or contract liabilities from contracts with customers. During the three months ended March 31, 2018 and 2017, there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. As of March 31, 2018, there were no remaining performance obligations that the Company had not satisfied.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4. Net Loss Per Common Share Basic loss per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted loss per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. As of March 31, 2018 2017 Stock options 722,446 707,328 Warrants 471,070 454,112 Non-vested restricted stock 193,006 82,667 Total 1,386,522 1,244,107

Inventory

Inventory	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventory March 31, December 31, 2018 2017 Raw materials $ 168 $ 98 Work in process 58 - Finished goods 1,497 1,521 Less: Inventory reserve for excess and slow moving inventory (68) (68) Total $ 1,655 $ 1,551

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Accrued Expenses and Other Current Liabilities March 31, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 2,386 $ 1,981 Milestone payment to licensor 1,000 1,000 Professional fees 841 538 Royalty fees 266 227 Deferred revenue 407 365 Other 225 159 Total accrued expenses and other current liabilities $ 5,125 $ 4,270

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt Instruments [Abstract]
Long-term Debt [Text Block]	Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “CAG”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The CAG provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75% is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000 11.4375 In connection with the CAG, the Company incurred approximately $ 1.3 57,000 64,000 In connection with the entry into the CAG, a five-year warrant (the “Warrant”) to purchase 75,000 0.001 55.138 2.7 134,000 140,000 Fair Value Measurement As of March 31, 2018, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the CAG as a result of the Company’s failure to achieve $ 27,200 30,300 33,800 37,800 40,000 2.0 The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 4.70 Fair Value Measurement March 31, December 31, 2018 2017 Principal balance $ 13,847 $ 12,135 Unamortized debt issuance and discount costs (1,016) (1,206) Total $ 12,831 $ 10,929 On March 13, 2018, Alliqua BioMedical, Inc., AquaMed Technologies, Inc., a wholly owned subsidiary of the Company, and Perceptive Credit Holdings, L.P. entered into an Amendment Agreement, pursuant to which the parties agreed to certain amendments and modifications to the terms of the Credit Agreement and Guaranty, dated May 29, 2015, by and among the Company, the Guarantor and Perceptive. The Amendment Agreement provides for, an additional bridge term loan to the Company in the aggregate principal amount of $ 2,000,000 250,000 The BLN bears interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%. On May 7, 2018, the Company extinguished the debt obligation, the BLN and associated fees relating to the aforementioned obligation.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Agreements for Human Placental Based Products Human Longevity, Inc. In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The agreements grant the Company an exclusive, royalty-bearing license in CCT’s intellectual property for certain placental based products, including ECM and Biovance ®, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, HLI Cellular Therapeutics, LLC (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. In June 2017, Celularity, Inc. (“Celularity”) acquired all of the assets of HLI, including the agreements between HLI and the Company. The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. For the three months ended March 31, 2018 and 2017, the Company incurred royalties of approximately $ 266,000 185,000 266,000 In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product, also known as Interfyl. In April 2016, the Company entered into a Supply Agreement with HLI (now Celularity), pursuant to which Celularity supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay Celularity $ 500,000 500,000 1.0 On December 1, 2017, we received notice from Celularity that we are in material breach of our License, Marketing and Development Agreement with Celularity (or its affiliates) dated as of November 14, 2013, as amended from time to time (the “License Agreement”) and our Supply Agreements with Celularity (or its affiliates), dated as of April 15, 2016 and November 14, 2013, respectively, as amended from time to time (the “Supply Agreements”) for failure to purchase the required amounts of materials under the Supply Agreements and failure to use commercially reasonable best efforts to undertake development activities for the licensed products under the License Agreement (the “Notices”). Celularity estimated that an additional purchase of at least $ 842,000 On May 7, 2018, the License Agreement and the Supply Agreements were transferred to Celularity in connection with the completion of the AST. License Agreement with Noble Fiber Technologies, LLC On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 600,000 43 1,900 Litigation, Claims and Assessments From time to time, the Company may become involved in lawsuits, investigations and claims that arise in the ordinary course of business. The Company believes it has meritorious defenses against all pending claims and intends to vigorously pursue them. While it is not possible to predict or determine the outcomes of any pending actions, the Company believes the amount of liability, if any, with respect to such actions, would not materially affect its financial position, results of operations or cash flows. On February 22, 2018, a putative stockholder class action complaint was filed in the United States District Court for the District of Delaware against the Company and each member of the Board, captioned Ronald Cresta, Individually and on Behalf of All Others Similarly Situated v. Alliqua BioMedical Inc., David Johnson, Joseph M. Leone, Gary Restani, Jeffrey Sklar and Mark Wagner. The complaint alleges, among other things, that the Company and the Board violated federal securities laws and regulations by soliciting stockholder votes in connection with the Asset Sale Transaction through a proxy statement that omits material facts necessary to make the statements therein not false or misleading. The complaint seeks, among other things, to enjoin the Company and the Board from conducting the stockholder vote on the Asset Sale Transaction unless and until the allegedly omitted material information is disclosed to the Company’s stockholders, damages allegedly suffered by the plaintiffs as a result of the asserted omissions, as well as related attorneys’ fees and expenses. On April 4, 2018, the court approved the parties’ stipulation and proposed order to withdraw the motion for preliminary injunction and dismiss the action and the case was closed. The court retained jurisdiction of the action solely for determining any potential fee application if the parties are unable to reach agreement and a fee application becomes necessary.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Stockholders’ Equity Stock-Based Compensation During the three months ended March 31, 2018, the Company recognized a credit of $ 80,000 14,000 94,000 491,000 11,000 480,000 343,000 0.7 Reverse Stock Split The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $ 0.001

Related Party

Related Party	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	10. Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then a member of the Board of Directors. During the three months ended March 31, 2018 and 2017, the Company incurred costs of approximately $ 189,000 127,000 122,000 102,000

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	11. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Warrant Liabilities On March 31, 2018, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 210,000 149,000 76.81 2.48 3.83 0.00 19,000 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Three Months Ended March 31, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 19 (118) Warrant modification expense - 770 Ending balance as of March 31, $ 149 $ 672 Three Months Ended March 31, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,350) Change in fair value of contingent consideration - 34 Ending balance as of March 31, $ - $ 500 March 31, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 149 Total liabilities $ - $ - $ 149 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expeced future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	12. Subsequent Event On May 7, 2018, the Company closed the APA with Celularity pursuant to which the Company sold substantially all of its assets to Celularity, including certain assets comprising its MIST, Biovance and Interfyl product lines. As consideration under the APA, Celularity paid 29 in cash. No debt or significant liabilities were assumed by Celularity associated with the APA. Under the terms of the APA, the Company will retain certain specified assets which include, cash, accounts receivable, and the Company’s hydrogel contract manufacturing business, including its SilverSeal and Hydress product The following proforma summary information reflects the Company’s balance sheet as if the APA closed on March 31, 2018. The below summary does not include all closing costs relating to the AST or the impact of the Company’s business operations for the period from April 1, 2018 through the date of closing. The proforma is meant only to depict the elimination of the March 31, 2018 balances for those assets that were part of the APA, in addition to the repayment of the Company’s outstanding debt with Perceptive. It was also meant to exclude the impact of certain transaction costs, including severance cost and other professional fees to be incurred during the Company’s second quarter, 2018. Upon the closing of the AST, substantially all of the inventory and fixed assets were part of the assets sold, and the goodwill and intangible assets related to those operations that remained on the Company’s books and records were eliminated. The Company’s cash position increased resulting from closing the AST, offset by the payment of its debt obligation including associated fees to Perceptive. ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) As Reported Proforma March 31, March 31, 2018 2018 (Unaudited) (Unaudited) ASSETS: Current Assets: Cash and cash equivalents $ 1,536 $ 15,735 Other current assets 6,062 4,545 Total current assets 7,598 20,280 Goodwill and intangible assets 22,594 - Other long term assets 1,558 619 Total assets $ 31,750 $ 20,899 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Senior secured debt $ 12,831 $ - Other current liabilities 8,149 6,743 Total current liabilities 20,980 6,743 Other liabilities 295 68 Total liabilities 21,275 6,811 Equity 10,475 14,088 Total liabilities and stockholders’ equity $ 31,750 $ 20,899

Description of Business and B19

Description of Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Recent Developments [Policy Text Block]	Recent Developments On January 5, 2018, the Company entered into an Asset Purchase Agreement (the “APA”) with Celularity, Inc. (“Celularity”) pursuant to which the Company agreed to sell substantially all of its assets to Celularity (the “Asset Sale Transaction”), including certain assets comprising its MIST, Biovance and Interfyl Product lines (the “Purchased Assets”). As consideration for the Purchased Assets, Celularity paid consideration to the Company $ 29 Under the terms of the APA, the Company will retain certain specified assets, including, among other things, cash, accounts receivable, and its hydrogel contract manufacturing business, including its SilverSeal and Hydress product lines. The transactions contemplated by the APA were approved by the affirmative vote of a majority of the voting power of issued and outstanding shares of the Company’s common stock on April 27, 2018. The AST was completed on May 7, 2018. The Company’s operations sold under the APA have not been reclassified to discontinued operations since they are classified as Held for Use. These operations are presented in continuing operations in the first quarter of 2018. These operations will be reclassified to discontinued operations in the second quarter of 2018, when the shareholders of the company approved the sale. (See Note 12 – Subsequent Events) The Company has, historically, served as a contract manufacturer, supplying the manufactured gels to third parties who incorporate them into their own products and will continue to manufacture said hydrogels going forward.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of March 31, 2018 and results of operations and cash flows for the three months ended March 31, 2018 and 2017. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations In order to add capital and to focus on future investments on commercializing its own regenerative technologies on August 31, 2017 the Company entered into an Asset Purchase Agreement (“the Argentum Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Argentum Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $ 3.6 112,000 3.6 300,000 100,000 200,000 Three Months Ended March 31, 2017 Revenue, net of returns, allowances and discounts $ 469 Cost of revenues 145 Gross profit 324 Selling, general and administrative 152 Income from discontinued operations, net of tax 172 Non-cash amortization expense of $ 74,000 March 31, December 31, 2018 2017 Accounts receivable, net $ 17 $ 17 Escrow 200 300 Total assets 217 317
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates Recent Accounting Principles In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Description of Business and B20

Description of Business and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the three months ended March 31, 2017 are presented in the following table, there are no operating results in 2018 (in thousands): Three Months Ended March 31, 2017 Revenue, net of returns, allowances and discounts $ 469 Cost of revenues 145 Gross profit 324 Selling, general and administrative 152 Income from discontinued operations, net of tax 172 Summarized assets of discontinued operations are presented in the following table (in thousands), there were no liabilities of discontinued operations for the three months ended March 31, 2018 and 2017 and all assets are considered current: March 31, December 31, 2018 2017 Accounts receivable, net $ 17 $ 17 Escrow 200 300 Total assets 217 317

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from External Customers by Products and Services [Table Text Block]	The following table presents our disaggregated revenues by revenue source (in millions). The Company recognizes revenue primarily from two different types of contracts, (i) product sales to customers and (ii) contract manufacturing. Revenue from sales of products as well as from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. Three Months Ended March 31, 2018 2017 Product $ 4,841 $ 3,896 Contract manufacturing 540 229 Total revenues, net $ 5,381 $ 4,125

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of March 31, 2018 2017 Stock options 722,446 707,328 Warrants 471,070 454,112 Non-vested restricted stock 193,006 82,667 Total 1,386,522 1,244,107

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (in thousands): March 31, December 31, 2018 2017 Raw materials $ 168 $ 98 Work in process 58 - Finished goods 1,497 1,521 Less: Inventory reserve for excess and slow moving inventory (68) (68) Total $ 1,655 $ 1,551

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following (in thousands): March 31, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 2,386 $ 1,981 Milestone payment to licensor 1,000 1,000 Professional fees 841 538 Royalty fees 266 227 Deferred revenue 407 365 Other 225 159 Total accrued expenses and other current liabilities $ 5,125 $ 4,270

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following (in thousands): March 31, December 31, 2018 2017 Principal balance $ 13,847 $ 12,135 Unamortized debt issuance and discount costs (1,016) (1,206) Total $ 12,831 $ 10,929

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Three Months Ended March 31, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 19 (118) Warrant modification expense - 770 Ending balance as of March 31, $ 149 $ 672 Three Months Ended March 31, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,350) Change in fair value of contingent consideration - 34 Ending balance as of March 31, $ - $ 500
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): March 31, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 149 Total liabilities $ - $ - $ 149 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130

Subsequent Event (Tables)

Subsequent Event (Tables)	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Pro Forma Summary Information As If The Apa Closed [Table Text Block]	ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) As Reported Proforma March 31, March 31, 2018 2018 (Unaudited) (Unaudited) ASSETS: Current Assets: Cash and cash equivalents $ 1,536 $ 15,735 Other current assets 6,062 4,545 Total current assets 7,598 20,280 Goodwill and intangible assets 22,594 - Other long term assets 1,558 619 Total assets $ 31,750 $ 20,899 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Senior secured debt $ 12,831 $ - Other current liabilities 8,149 6,743 Total current liabilities 20,980 6,743 Other liabilities 295 68 Total liabilities 21,275 6,811 Equity 10,475 14,088 Total liabilities and stockholders’ equity $ 31,750 $ 20,899

Description of Business and B28

Description of Business and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, net of returns, allowances and discounts		$ 469
Cost of revenues		145
Gross profit		324
Selling, general and administrative		152
Income from discontinued operations, net of tax	$ 0	$ 172

Description of Business and B29

Description of Business and Basis of Presentation (Details 1) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 17	$ 17
Escrow	200	300
Total assets	$ 217	$ 317

Description of Business and B30

Description of Business and Basis of Presentation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jan. 05, 2018	Dec. 31, 2017	Aug. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Maximum Amount To be Received for Unsold Inventory					$ 112,000
Disposal Group, Including Discontinued Operation, Consideration				$ 3,600,000	$ 3,600,000
Disposal Group, Including Discontinued Operation, Escrow Deposit, Current	$ 200,000			$ 300,000
Payments for (Proceeds from) Deposit on Loan	100,000
Escrow Deposit	$ 200,000
Celularity, Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration			$ 29,000,000
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets		$ 74,000

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Net Income (Loss) Attributable to Parent, Total	$ (5,110)	$ (6,998)
Net Cash Provided by (Used in) Operating Activities	(2,455)	(4,646)
Retained Earnings (Accumulated Deficit), Total	(155,120)		$ (150,010)
Cash and Cash Equivalents, at Carrying Value, Total	1,536	$ 2,350	2,181	$ 5,580
Long-term Debt, Total	12,831		$ 10,929
Proceeds from Lines of Credit	$ 29,000

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017
Product	$ 4,841	$ 3,896
Contract manufacturing	540	229
Total revenues, net	$ 5,381	$ 4,125	$ 37,800	$ 33,800	$ 30,300	$ 27,200

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,386,522	1,244,107
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	722,446	707,328
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	471,070	454,112
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	193,006	82,667

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 168	$ 98
Work in process	58	0
Finished goods	1,497	1,521
Less: Inventory reserve for excess and slow moving inventory	(68)	(68)
Total	$ 1,655	$ 1,551

Accrued Expenses and Other Cu35

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 2,386	$ 1,981
Milestone payment to licensor	1,000	1,000
Professional fees	841	538
Royalty fees	266	227
Deferred revenue	407	365
Other	225	159
Total accrued expenses and other current liabilities	$ 5,125	$ 4,270

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal balance	$ 13,847	$ 12,135
Unamortized debt issuance and discount costs	(1,016)	(1,206)
Total	$ 12,831	$ 10,929

Debt (Details Textual)

Debt (Details Textual) - USD ($)	Mar. 13, 2018	May 29, 2015	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 01, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									210,000
Common Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 55.138						$ 4.70
Derivative Liability			$ 149,000	$ 672,000	$ 130,000			$ 672,000		$ 20,000
Amortization of Debt Discount (Premium)			$ 190,000	204,000
Debt Instrument, Term			4 years
Warrant Expiration Period			five-year warrant
Common Stock Purchased By Warrants Issued			75,000
Debt Instrument Prepayment Terms					is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date 
Exit fee payment, Credit Agreement Description		The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000	amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000. The interest rate at March 31, 2018 was 11.4375%.
Revenues			$ 5,381,000	4,125,000	$ 37,800,000	$ 33,800,000	$ 30,300,000	$ 27,200,000
Bridge Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 2,000,000
Debt Instrument, Interest Rate Terms	The BLN bears interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%.
Debt Instrument, Maturity Date	May 4, 2018
Upfront Fee Payable	$ 250,000
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability			149,000		$ 130,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability			2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs			57,000	64,000
Amortization of Debt Discount (Premium)			134,000	$ 140,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 15,500,000
Debt Issuance Costs1			$ 1,300,000
Debt Instrument, Interest Rate Terms		accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Payment Terms		is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Maturity Date, Description		The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000, which was amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000.
Debt Instrument, Interest Rate During Period			11.4375%
Debt Instrument, Debt Default, Amount			$ 2,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Dec. 01, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Royalty Expense			$ 266,000	$ 186,000
Accrued Liabilities, Current			5,125,000		$ 4,270,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months						$ 600,000
Royalty Expense			43	1,900
Human Longevity, Inc [Member]
Commitments And Contingencies [Line Items]
Royalty Expense			266,000	$ 185,000
Accrued Liabilities, Current			266,000
Revenue Recognition, Milestone Method, Milestone Expenses			1,000,000
Human Longevity, Inc [Member] | First Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months			500,000
Human Longevity, Inc [Member] | Second Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months			$ 500,000
Cellularity Inc [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount		$ 842,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Oct. 05, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 80,000	$ 491,000
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Stockholders' Equity, Reverse Stock Split	1-for-10
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 14,000	11,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		94,000	$ 480,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 343,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		8 months 12 days

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 189,000	$ 127,000
Accounts Payable, Related Parties	$ 122,000		$ 102,000

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 130	$ 20
Change in fair value of warrant liability	19	(118)
Warrant modification expense	0	770
Ending balance	149	672
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	0	1,816
Change in fair value of warrant liability	0	34
Payments of contingent consideration	0	(1,350)
Ending balance	$ 0	$ 500

Fair Value Measurement (Detai42

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Liabilities:
Warrant liabilities	$ 149	$ 130	$ 672	$ 20
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	149	130
Total liabilities	$ 149	$ 130

Fair Value Measurement (Detai43

Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 149	$ 672	$ 130	$ 20
Fair Value Adjustment of Warrants	$ 19	$ (118)
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock	210,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 149		$ 130
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	76.81%
Fair Value Assumptions, Risk Free Interest Rate	2.48%
Fair Value Assumptions, Expected Term	3 years 9 months 29 days
Fair Value Assumptions, Expected Dividend Rate	0.00%

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 1,536
Other current assets	6,062
Total current assets	7,598	$ 7,477
Goodwill and intangible assets	22,594
Other long term assets	1,558
Total assets	31,750	32,941
Current Liabilities:
Senior secured debt	12,831	10,929
Other current liabilities	8,149
Total current liabilities	20,980	16,970
Other liabilities	295
Total liabilities	21,275	17,274
Equity	10,475	15,667
Total liabilities and stockholders’ equity	31,750	$ 32,941
Pro Forma [Member]
Current Assets:
Cash and cash equivalents	15,735
Other current assets	4,545
Total current assets	20,280
Goodwill and intangible assets	0
Other long term assets	619
Total assets	20,899
Current Liabilities:
Senior secured debt	0
Other current liabilities	6,743
Total current liabilities	6,743
Other liabilities	68
Total liabilities	6,811
Equity	14,088
Total liabilities and stockholders’ equity	$ 20,899

Subsequent Event (Details Textu

Subsequent Event (Details Textual) $ in Millions	May 07, 2018USD ($)
Subsequent Event [Member] | Purchase Agreement [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock And Debt	$ 29